Therapies directly targeting GBA + PD are now under clinical studies, such as chaperons (ambroxol, arimoclomol, and isofagomine), autophagy enhancers (rapamycin and polyphenols), ibiglustat (which reduces GCase levels), and GZ667161 (a glucosylceramide synthase). Here, GBA1 is linked to Parkinson disease.